Display options
Cite
Wada T, Nishiyama K, Nakatani Y, et al. CAF versus CAF plus Medroxyprogesterone Acetate for Treatment of Liver Metastases of Breast Cancer. Breast Cancer. 1995;2(1):65-70doi: 10.1007/BF02966898.
Wada, T., Nishiyama, K., Nakatani, Y., Houjou, T., Inui, H., Yamauchi, E., Hara, S., & Yasutomi, M. (1995). CAF versus CAF plus Medroxyprogesterone Acetate for Treatment of Liver Metastases of Breast Cancer. Breast cancer (Tokyo, Japan), 2(1), 65-70. https://doi.org/10.1007/BF02966898
Wada, et al. "CAF versus CAF plus Medroxyprogesterone Acetate for Treatment of Liver Metastases of Breast Cancer." Breast cancer (Tokyo, Japan) vol. 2,1 (1995): 65-70. doi: https://doi.org/10.1007/BF02966898
Wada T, Nishiyama K, Nakatani Y, Houjou T, Inui H, Yamauchi E, Hara S, Yasutomi M. CAF versus CAF plus Medroxyprogesterone Acetate for Treatment of Liver Metastases of Breast Cancer. Breast Cancer. 1995 Apr 30;2(1):65-70. doi: 10.1007/BF02966898. PMID: 11091534.
Copy Download .nbib Format: NLM
Share it on

Breast Cancer. 1995 Apr 30;2(1):65-70. doi: 10.1007/BF02966898.

CAF versus CAF plus Medroxyprogesterone Acetate for Treatment of Liver Metastases of Breast Cancer.

Breast cancer (Tokyo, Japan)

Wada, Nishiyama, Nakatani, Houjou, Inui, Yamauchi, Hara, Yasutomi

Affiliations

  1. First Department of Surgery, Kinki University, 377 Ohnohigashi, Osaka-Sayama 589, Japan.

PMID: 11091534 DOI: 10.1007/BF02966898

Abstract

A controlled randomized trial was conducted to compare the effectiveness of a CAF therapy including cyclophosphamide (CPA), adriamycin (ADR) and 5-fluorouracil (5FU) with that of CAF plus medroxyprogesterone acetate (MPA) therapy including CPA, ADR and 5FU plus MPA for the treatment of liver metastases from breast cancer. A total of 34 patients with unresectable liver metastases from breast cancer were divided into two treatment groups(CAF and CAF + MPA)with stratification for estrogen receptor status. The response rate was 13%(2PR in 16 patients)for CAF therapy and 22% (1 CR and 3 PR in 18 patients) for CAF plus MPA therapy. There was no significant difference in response rates, median survival periods and survival rates between the two treatment groups. However, CAF therapy had significantly more toxicity than did CAF plus MPA therapy. The findings of this study suggested that CAF plus MPA therapy is a well-tolerated and effective treatment for patients with liver metastases of breast cancer.

References

  1. Breast Cancer. 1994 Jul 30;1(1):51-56 - PubMed
  2. Int J Radiat Oncol Biol Phys. 1983 Mar;9(3):279-97 - PubMed
  3. Cancer. 1986 Jan 1;57(1):87-91 - PubMed
  4. Cancer. 1977 Aug;40(2):625-32 - PubMed
  5. Acta Endocrinol (Copenh). 1976 May;82(1):105-20 - PubMed
  6. Breast Cancer Res Treat. 1988 Oct;12(2):213-25 - PubMed
  7. Jpn J Clin Oncol. 1993 Aug;23(4):250-7 - PubMed
  8. Anticancer Res. 1986 Sep-Oct;6(5):1095-9 - PubMed
  9. Hepatology. 1986 May-Jun;6(3):440-3 - PubMed
  10. J Clin Oncol. 1987 May;5(5):773-82 - PubMed
  11. Gan To Kagaku Ryoho. 1989 May;16(5):2087-92 - PubMed
  12. Breast Cancer Res Treat. 1983;3(2):231-5 - PubMed
  13. Semin Oncol. 1986 Dec;13(4 Suppl 4):2-8 - PubMed
  14. Cancer Chemother Pharmacol. 1984;13(2):95-9 - PubMed
  15. Semin Oncol. 1983 Jun;10(2):148-58 - PubMed
  16. Eur J Cancer. 1992;28(2-3):390-4 - PubMed
  17. Cancer. 1972 Dec;30(6):1543-55 - PubMed
  18. Jpn J Clin Oncol. 1991 Oct;21(5):334-9 - PubMed

Publication Types